Moderna Reports 41% Revenue Decline in Q2 2025, Launches $1.5 Billion Cost-Cutting Initiative
Key Insights
Moderna's Q2 2025 revenue dropped 41% to $142 million compared to $241 million in the same period last year, primarily driven by declining COVID (search) vaccine sales.
The company announced a comprehensive $1.5 billion, three-year cost-cutting plan that includes eliminating over 800 jobs while winding down new R&D efforts and optimizing procurement processes.
Despite current challenges, Moderna revised its 2025 revenue projection to $1.5-$2.2 billion and expects sales growth in the second half of the year during RSV (search), flu, and COVID (search) seasons.
Moderna reported a significant 41% decline in second quarter 2025 revenue to $142 million, down from $241 million in the same period last year, as the mRNA vaccine pioneer implements a sweeping $1.5 billion cost-cutting plan to navigate challenging market conditions.
The Cambridge-based biotechnology company's financial results reflect the ongoing impact of reduced COVID (search) vaccine demand, with COVID vaccine sales totaling $114 million in the quarter. The company also recorded a GAAP net loss of $0.8 billion, translating to a loss per share of $2.13.
Strategic Cost Reduction Initiative
Moderna's comprehensive three-year cost-cutting plan focuses primarily on winding down new R&D efforts and optimizing procurement processes. The initiative will result in the elimination of over 800 jobs, though the company plans to maintain 150 open vacancies for continued recruitment in strategic areas.
The cost reduction measures are expected to decrease operating expenses by $400 million, with total operating expenses now projected to range from $5.9 to $6.1 billion. Research and development expenses for full-year 2025 are expected to be $3.6 to $3.8 billion, representing a decrease from previous expectations of approximately $4.1 billion.
Revenue Projections and Market Outlook
Moderna has updated its 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end. This adjustment is primarily attributed to the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026.
Despite current financial challenges, analyst Anaelle Tannen notes that sales may increase in the second half of the year as the RSV (search), flu, and COVID (search) seasons hit the northern hemisphere. The company's strategic focus on seasonal vaccines and other therapeutic areas may drive sales growth in the latter half of the year.
Pipeline Progress and Product Performance
Moderna's Q2 2025 sales included contributions from Spikevax® and mNEXSPIKE (search)®, though the company experienced limited RSV (search) vaccine sales despite expanded approvals for usage in at-risk adults. Recent FDA approvals and positive Phase 3 efficacy results for the company's seasonal influenza (search) vaccine indicate strong progress in its pipeline development.
The company maintains its anticipated year-end cash reserve of approximately $6 billion, providing financial stability during this period of operational restructuring. R&D and administrative expenses decreased significantly during the quarter, demonstrating ongoing cost discipline and operational streamlining efforts.